SillaJen, Inc. (KOSDAQ:215600)

Market Cap	531.80B
Revenue (ttm)	7.84B
Net Income (ttm)	-23.24B
Shares Out	138.13M
EPS (ttm)	-168.95
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	12,022,800
Average Volume	1,536,678
Open	3,465.00
Previous Close	3,435.00
Day's Range	3,415.00 - 3,950.00
52-Week Range	1,873.00 - 4,700.00
Beta	0.04
RSI	81.49
Earnings Date	Aug 12, 2025

About SillaJen

SillaJen, Inc. engages in developing technologies and products using genetic engineering in South Korea. The company develops Pexa-Vec, which is in phase 2 clinical trial to treat renal Cell Carcinoma and prostate cancer, as well as in phase 1 clinical trial to treat melanoma and solid tumors. It also develops BAL0891, which is in phase 1 clinical trial for the treatment of solid tumors; and SJ-600 Series and JX-970 to treat solid tumors and is in preclinical trial. SillaJen, Inc. was founded in 2006 and is headquartered in Seoul, South Korea.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2006
• Employees: 37
• Stock Exchange: KOSDAQ
• Ticker Symbol: 215600

Financial Performance

In 2024, SillaJen's revenue was 3.93 billion, a decrease of -0.33% compared to the previous year's 3.94 billion. Losses were -26.53 billion, 30.2% more than in 2023.